Balance Sheet

v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash $ 18,785 $ 279,772
Accounts receivable, net 11,250 8,000
Prepaid expenses 88,101 31,458
Total current assets 118,136 319,230
Property and equipment, net 80,089 44,369
Right to use assets, net 12,863
Other assets:    
Patents 15,200 15,200
Intellectual property, net 236,000 236,000
Deposits, long term 13,422 13,422
Total other assets 264,622 264,622
Total assets 475,710 628,221
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $47,998 and $32,318, respectively 1,638,893 1,554,652
Deferred revenue, short term 161,266 209,474
Deferred revenue-grant 66,000
Lease liability 13,245
Convertible notes payable, short term portion, net of debt discount of $289,394 and $656,231 3,870,606 3,503,769
Notes payable, short term portion, net of debt discounts of $79,815 and $127,419 720,185 672,581
Notes payable, related party 186,590 186,590
Total current liabilities 6,656,785 6,127,066
Long term debt:    
Deferred revenue, long term 197,207 207,523
Total liabilities 6,853,992 6,334,589
Commitments and contingencies
Deficit:    
Preferred stock value 16,000 16,000
Common stock, $0.001 par value; 750,000,000 shares authorized, 3,030,124 and 2,597,347 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 3,030 2,597
Common stock subscribed 100,000 100,000
Common stock subscription receivable ( Note 11) (1,560,000)
Additional paid in capital 52,076,488 49,418,356
Accumulated deficit (56,946,901) (55,176,450)
Total stockholders' deficit attributable to BioCorRx, Inc. (6,305,767) (5,633,881)
Non-controlling interest (72,515) (72,487)
Total deficit (6,378,282) (5,706,368)
Total liabilities and deficit 475,710 628,221
Series B Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616

Source